Granulocyte-colony stimulating factor improves Parkinson′s disease associated with co-morbid depression: An experimental exploratory study

Indian Journal of Pharmacology

Volumn 45, Issue 6, 2013, Pages 612-615

  Prakash, Ajay ^b   Chopra, Kanwaljit ^a   Medhi, Bikash ^b  

^a University Institute of Pharmaceutical Sciences   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

6 hydroxydopamine; depression; forced swim test; granulocyte colony stimulating factor; Parkinson s disease

Indexed keywords

CARBIDOPA PLUS LEVODOPA; GRANULOCYTE COLONY STIMULATING FACTOR; LEVODOPA; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FORCED SWIMMING TEST; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE;

6-HYDROXYDOPAMINE; DEPRESSION; FORCED SWIM TEST; GRANULOCYTE-COLONY STIMULATING FACTOR; PARKINSON'S DISEASE;

ANIMALS; DEPRESSION; GRANULOCYTE COLONY-STIMULATING FACTOR; MALE; PARKINSON DISEASE; RATS; RATS, WISTAR;

EID: 84890054816     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.121374     Document Type: Article

References (23)

1. Siderowf A, Stern M. Update on Parkinson disease. Ann Intern Med 2003; 138: 651- 8.
2. Cummings JL. Depression and Parkinson's disease: A review. Am J Psychiatry 1992; 149: 443-54.
3. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
4. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55: 259-72.
5. Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000; 15: 1112-8.
6. Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci 2006; 248: 151-7.
7. Antonini A. Unraveling depression in Parkinson's disease. Eur J Neurol 2008; 15: 885-6.
8. Prado RC, Barbosa ER. Depression in Parkinson's disease: Study of 60 cases. Arq Neuropsiquiatr 2005; 63: 766-71.
9. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, et al. Depression rating scales in Parkinson's disease: Critique and recommendations. Mov Disord 2007; 22: 1077-92.
10. Grigg AP, Roberts AW, Raunow H, Houghton S, Layton JE, Boyd AW, et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437-45.
11. Khan M, Sekhon B, Giri S, Jatana M, Gilg AG, Ayasolla K, et al. S-Nitrosoglutathione reduces inflammation and protects brain against focal cerebral ischemia in a rat model of experimental stroke. J Cereb Blood Flow Metab 2005; 25: 177-92.
12. Komine-Kobayashi M, Zhang N, Liu M, Tanaka R, Hara H, Osaka A, et al. Neuroprotective effect of recombinant human granulocyte colonystimulating factor in transient focal ischemia of mice. J Cereb Blood Flow Metab 2006; 26: 402-13.
13. Gibson CL, Jones NC, Prior MJ, Bath PM, Murphy SP. G-CSF suppresses edema formation and reduces interleukin-1beta expression after cerebral ischemia in mice. J Neuropathol Exp Neurol 2005; 64: 763-9.
14. Vernon AC, Palmer S, Datla KP, Zbarsky V, Croucher MJ, Dexter DT. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur J Neurosci 2005; 22: 1799-806.
15. Chan H, Paur H, Vernon AC, Zabarsky V, Datla KP, Croucher MJ, et al. Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease. Parkinsons Dis 2010; 2010: pii: 190450.
16. Freret T, Bouet V, Leconte C, Roussel S, Chazalviel L, Divoux D, et al. Behavioral deficits after distal focal cerebral ischemia in mice: Usefulness of adhesive removal test. Behav Neurosci 2009; 123: 224-30.
17. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977; 229: 327-36.
18. Burke RE, Macaya A, DeVivo D, Kenyon N, Janec EM. Neonatal hypoxicischemic or excitotoxic striatal injury results in a decreased adult number of substantia nigra neurons. Neuroscience 1992; 50: 559-69.
19. Bouet V, Boulouard M, Toutain J, Divoux D, Bernaudin M, Schumann-Bard P, et al. The adhesive removal test: A sensitive method to assess sensorimotor deficits in mice. Nat Protoc 2009; 4: 1560-4.
20. Song S, Sava V, Rowe A, Li K, Cao C, Mori T, et al. Granulocyte-colony stimulating factor (G-CSF) enhances recovery in mouse model of Parkinson's disease. Neurosci Lett 2011; 487: 153-7.
21. Cao XQ, Arai H, Ren YR, Oizumi H, Zhang N, Seike S, et al. Recombinant human granulocyte colony-stimulating factor protects against MPTPinduced dopaminergic cell death in mice by altering Bcl-2/Bax expression levels. J Neurochem 2006; 99: 861-7.
22. Meuer K, Pitzer C, Teismann P, Krüger C, Göricke B, Laage R, et al. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease. J Neurochem 2006; 97: 675-86.
23. Schneider A, Krüger C, Steigleder T, Weber D, Pitzer C, Laage R, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005; 115: 2083-98.